48 results
PRER14A
GLSHQ
Gelesis Holdings, Inc.
7 Sep 23
Preliminary revised proxy
4:03pm
for consumer engagement. It is focused on advancing first-in-class superabsorbent hydrogel therapeutics for chronic gastrointestinal (“GI”), diseases … potential therapeutic candidates for common chronic conditions affected by gut health that are currently in clinical and preclinical testing, including type
PREM14A
GLSHQ
Gelesis Holdings, Inc.
24 Jul 23
Preliminary proxy related to merger
9:47pm
built for consumer engagement. It is focused on advancing first-in-class superabsorbent hydrogel therapeutics for chronic gastrointestinal (“GI … for common chronic conditions affected by gut health that are currently in clinical and preclinical testing, including type 2 diabetes, NAFLD, NASH
424B3
94d u0r478r8
16 Nov 22
Prospectus supplement
4:51pm
424B3
2ev5qkrw6ebx64v34u
16 Nov 22
Prospectus supplement
4:48pm
8-K
EX-99.1
t8n57vh 3blurfusrrs1
14 Nov 22
Gelesis Reports Third Quarter 2022 Results
8:56am
424B3
3sfhtx0g
16 Sep 22
Prospectus supplement
11:19am
424B3
9cecnt5
6 Sep 22
Prospectus supplement
4:53pm
8-K
EX-99.1
k9yzdhjx
15 Aug 22
Gelesis Reports Second Quarter 2022 Results
7:01am
8-K
EX-10.1
l93dd dfssvgjtj
12 Aug 22
Entry into a Material Definitive Agreement
4:02pm
424B3
0zw6d1iz54k
8 Jun 22
Prospectus supplement
4:21pm
8-K
EX-99.1
52s6e4 xg
12 May 22
Results of Operations and Financial Condition
4:01pm